Illinois News Desk

The Systemic Lupus Erythematosus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Systemic Lupus Erythematosus Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Systemic Lupus Erythematosus Market.

Some of the key takeaways from the Systemic Lupus Erythematosus Pipeline Report:

• Companies across the globe are diligently working toward developing novel Systemic Lupus Erythematosus treatment therapies with a considerable amount of success over the years. 
• Systemic Lupus Erythematosus companies working in the treatment market are I-Mab Biopharma, Roche, Equillium, Biocon Limited, Kangpu Biopharmaceuticals, Boston Pharmaceuticals, Nektar Therapeutics, AbbVie, Horizon Therapeutics, Sanofi, Biogen, Hoffman-La-Roche, ImmuPharma, Eli Lilly and Company, Bristol Myers Squibb, and others, are developing therapies for the Systemic Lupus Erythematosus treatment 

• Emerging Systemic Lupus Erythematosus therapies in the different phases of clinical trials are- TJ202, Mosunetuzumab, Itolizumab, KPG 818, BOS161721, NKTR-358, ABBV-599, Daxdilimab (VIB7734), SAR441344, BIIB059, Obinutuzumab, Forigerimod, Baricitinib, BIIB059, Deucravacitinib, and others are expected to have a significant impact on the Systemic Lupus Erythematosus market in the coming years.
• In October 2022, Alpine Immune Sciences, Inc. declared that it will be presenting poster presentations for ALPN-303’s phase 1 trial (RUBY-1) at forthcoming scientific conferences.
• In October 2022, Data from several trials on LUPKYNIS® (voclosporin) will be presented during the American Society of Nephrology (ASN) Kidney Week 2022, which will take place in Orlando, Florida from November 3–6, 2022, according to a statement released by Aurinia Pharmaceuticals Inc.  
• On February 1, 2022, Biogen Inc. declared that it had acted on its option to take part in mosunetuzumab development and commercialization. As part of their long-standing cooperation on CD20-targeting antibodies, Biogen and Genentech, both members of the Roche Group, will split a one-time option fee of $30 million. In patients with SLE, mounetuzumab is presently in Phase Ib of development.
• In February 2022, Benlysta from GlaxoSmithKline is now authorized for use in the treatment of adult patients with active lupus nephritis (LN) in China by the National Medical Products Administration (NMPA).
• In February 2022, In spite of receiving standard treatment, adult patients with moderate to severe active autoantibody-positive systemic lupus erythematosus (SLE) may now get AstraZeneca’s Saphnelo (anifrolumab) as an add-on therapy in the EU.
• A Phase IIb study is being conducted to treat patients with Systemic Lupus Erythematosus using rozibafusp alfa, a multispecific antibody-peptide fusion that concurrently suppresses the function of B-cell activating factor (BAFF) and inducible T-cell costimulatory ligand (ICOSL).

Systemic Lupus Erythematosus Overview

An autoimmune illness affecting several systems, systemic lupus erythematosus (SLE) is linked to a high rate of morbidity and mortality. The loss of immunological tolerance to self-antigens is influenced by genetic, immunological, endocrine, and environmental variables. This leads to the development of pathogenic autoantibodies, which harm tissue in a number of ways.

Get a Free Sample PDF Report to know more about Systemic Lupus Erythematosus Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/systemic-lupus-erythematosus-pipeline-insight

Emerging Systemic Lupus Erythematosus Drugs Under Different Phases of Clinical Development Include:

• TJ202: I-Mab Biopharma
• Mosunetuzumab: Roche
• Itolizumab: Equillium/ Biocon Limited
• KPG 818: Kangpu Biopharmaceuticals
• BOS161721: Boston Pharmaceuticals
• NKTR-358: Nektar Therapeutics
• ABBV-599: AbbVie
• Daxdilimab (VIB7734): Horizon Therapeutics
• SAR441344: Sanofi
• BIIB059: Biogen
• Obinutuzumab: Hoffman-La-Roche
• Forigerimod: ImmuPharma
• Baricitinib: Eli Lilly and Company
• BIIB059: Biogen
• Deucravacitinib: Bristol Myers Squibb

Systemic Lupus Erythematosus Route of Administration

Systemic Lupus Erythematosus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Systemic Lupus Erythematosus Molecule Type

Systemic Lupus Erythematosus Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

Systemic Lupus Erythematosus Pipeline Therapeutics Assessment

• Systemic Lupus Erythematosus Assessment by Product Type
• Systemic Lupus Erythematosus By Stage and Product Type
• Systemic Lupus Erythematosus Assessment by Route of Administration
• Systemic Lupus Erythematosus By Stage and Route of Administration
• Systemic Lupus Erythematosus Assessment by Molecule Type
• Systemic Lupus Erythematosus by Stage and Molecule Type

DelveInsight’s Systemic Lupus Erythematosus Report covers around 60+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Systemic Lupus Erythematosus product details are provided in the report. Download the Systemic Lupus Erythematosus pipeline report to learn more about the emerging Systemic Lupus Erythematosus therapies

Some of the key companies in the Systemic Lupus Erythematosus Therapeutics Market include:

Key companies developing therapies for Systemic Lupus Erythematosus are – AstraZeneca, Eli Lilly and Company, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb, Kumming Pharmaceuticals, Alpine Immune Sciences, Sanofi, Momenta Pharmaceuticals, Pfizer, Idorsia Pharmaceuticals, Resolve Therapeutics, ILTOO Pharma, Amgen, AbbVie, Novartis, Corestem, Corbus Pharmaceuticals, Viela Bio, Janssen Biotech, Boston Pharmaceuticals, InnoCare Pharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, ACEA therapeutics, Mitsubishi Tanabe Pharma Corporation, and others.

Systemic Lupus Erythematosus Pipeline Analysis:

The Systemic Lupus Erythematosus pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Systemic Lupus Erythematosus with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Systemic Lupus Erythematosus Treatment.
• Systemic Lupus Erythematosus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Systemic Lupus Erythematosus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Systemic Lupus Erythematosus market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Systemic Lupus Erythematosus drugs and therapies

Systemic Lupus Erythematosus Pipeline Market Drivers

• Promising Therapeutic Approaches, Increasing Awareness of the Disease, Recent Advancements in Research and Development are some of the important factors that are fueling the Systemic Lupus Erythematosus Market.

Systemic Lupus Erythematosus Pipeline Market Barriers

• However, obstacles in SLE Pipeline, hit and Trial Approach of Researchers, high Annual Cost of Therapies and other factors are creating obstacles in the Systemic Lupus Erythematosus Market growth.

Scope of Systemic Lupus Erythematosus Pipeline Drug Insight    

• Coverage: Global
• Key Systemic Lupus Erythematosus Companies: I-Mab Biopharma, Roche, Equillium, Biocon Limited, Kangpu Biopharmaceuticals, Boston Pharmaceuticals, Nektar Therapeutics, AbbVie, Horizon Therapeutics, Sanofi, Biogen, Hoffman-La-Roche, ImmuPharma, Eli Lilly and Company, Bristol Myers Squibb, and others
• Key Systemic Lupus Erythematosus Therapies: TJ202, Mosunetuzumab, Itolizumab, KPG 818, BOS161721, NKTR-358, ABBV-599, Daxdilimab (VIB7734), SAR441344, BIIB059, Obinutuzumab, Forigerimod, Baricitinib, BIIB059, Deucravacitinib, and others
• Systemic Lupus Erythematosus Therapeutic Assessment: Systemic Lupus Erythematosus current marketed and Systemic Lupus Erythematosus emerging therapies
• Systemic Lupus Erythematosus Market Dynamics: Systemic Lupus Erythematosus market drivers and Systemic Lupus Erythematosus market barriers 

Request for Sample PDF Report for Systemic Lupus Erythematosus Pipeline Assessment and clinical trials

Table of Contents

1. Systemic Lupus Erythematosus Report Introduction

2. Systemic Lupus Erythematosus Executive Summary

3. Systemic Lupus Erythematosus Overview

4. Systemic Lupus Erythematosus- Analytical Perspective In-depth Commercial Assessment

5. Systemic Lupus Erythematosus Pipeline Therapeutics

6. Systemic Lupus Erythematosus Late Stage Products (Phase II/III)

7. Systemic Lupus Erythematosus Mid Stage Products (Phase II)

8. Systemic Lupus Erythematosus Early Stage Products (Phase I)

9. Systemic Lupus Erythematosus Preclinical Stage Products

10. Systemic Lupus Erythematosus Therapeutics Assessment

11. Systemic Lupus Erythematosus Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Systemic Lupus Erythematosus Key Companies

14. Systemic Lupus Erythematosus Key Products

15. Systemic Lupus Erythematosus Unmet Needs

16 . Systemic Lupus Erythematosus Market Drivers and Barriers

17. Systemic Lupus Erythematosus Future Perspectives and Conclusion

18. Systemic Lupus Erythematosus Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services